my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
NeuroSearch is dedicated to the discovery and development of medicines to satisfy unmet medical needs. NeuroSearch’s core business focuses on diseases of the central nervous system primarily treated through modulation of ion channels and other membrane-bound transporters. more
Cytochroma announced the appointment of Peter Moldt, PhD to its Board of Directors. Dr. Moldt will replace Mr. Ulrik Spork as the Novo A/S representative on the Company's Board. The number of Board members remains unchanged at six members. Dr. Moldt has experience in corporate strategy, company ope more
According to trials, a new obesity drug, Tesofensine, which may be launched on the world market in a few years, can produce weight loss twice that of currently approved obesity drugs. The Danish company Neurosearch and a number of researchers at the Faculty of Life Sciences at University of Copenhag more
Nuevolution A/S announced that Knud Aunstrup is stepping down as the company's CEO and that he will be replaced in the position by Alex Haahr Gouliaev. The new management team of Nuevolution now comprises Alex Haahr Gouliaev (CEO), Henrik Pedersen (CSO) and Mark Payne (CFO).Knud Aunstrup will remain more
What will this decade hold for the challenged anti-obesity drug industry and market? Our new report gives you revenue forecasts at world, product and national level. We provide original research, data and opinions to benefit your work. By ordering now, you can stay ahead. We aim to save you time a more
Introduction GlobalData, the industry analysis specialist, has released its new report, “Huntington’s Disease (HD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Huntington’s Disease Therapeutics market. more
Participants This page will be updated continuously during the registration period. Denmark Syntese A/S Mikael Munch-Pedersen Syntese A/S Asbjörn Klerke Syntese A/S Michael Henriksen Niels Clauson-Kaas A/S Peter Sivertsen Niels Clauson-Kaas A/S Anders Lohse Niels Clauson-Kaas A/S Chr more
Companies Pharmaceuticals Grupo Ferrer Internacional, S.A. Ferrer Internacional, S.A. Laboratorios Novag, S.A. Laboratorios Robert, S.A. Ferrer Farma, S.A. Ferrer inCode, S.L. Tarbis Farma, S.L. Laboratorios OTC Ibérica, S.A. Laboratorios Gelos, S.L. Bioprojet-Ferrer, S.L. Brainpharma, S.L. Oncnosis more
About Us Technology Board Investors Management News Room Contact Board Hans T. Schambye, MD PhD Chairman of Rose’s Board of Directors. Dr. Schambye previously served as Gastrotech's Chief Executive Officer. Before joining Gastrotech, Dr. Schambye served as Director of Biology and Pharmacology an more
Watchlist
This is where you can add this topic to your personal favourites
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
